Fulgent Genetics reported record third-quarter revenue of $101.7 million, an 883% increase year-over-year. GAAP earnings were $46.6 million, or $1.98 per share, and non-GAAP earnings were $49.0 million, or $2.08 per share. The company raised its full-year revenue guidance to $235 million.
Record revenue of $101.7 million, growing more than 880% year-over-year.
Record billable tests delivered approximately 1.04 million, growing more than 4,800% year-over-year.
Gross Margin improved approximately 19 percentage points sequentially and approximately 12 percentage points year-over-year.
Non-COVID Revenue grew 57% sequentially.
The company expects to generate revenue of at least $110 million for the fourth quarter of 2020 and now expects revenue of $235 million for the full year 2020.
Analyze how earnings announcements historically affect stock price performance